This award underscores the critical importance of advancing brain disease product development and the need to improve patient lives. Reglagene’s commitment to groundbreaking solutions remains steadfast, and we're excited for the future!

Richard Austin and Michael Abrahamson are joined by Board Chair Lawrence Kinet, Tripp Shannon, CFA, and Jeff Koenig at Seattle’s Keiretsu Syndication Summit & Keiretsu Family Office Forum.

Dr. Richard Austin will be presenting Reglagene at the Keiretsu Family Office Forum on August 16, 2023.

Reglagene's CEO Richard Austin is attending the 2023 SNO/ASCO CNS Cancer Conference.

This step confirms the safety and pharmacological activity exhibited by a drug for commercial development and paves the way to the next step: the initiation of human clinical trials.

Reglagene is honored to announce our partnership with Tech Coast Angels.

We have an incredible opportunity to join our team for a 3 month internship.

At BIO2023, we presented our new preclinical efficacy data demonstrating Reglagene’s medicine outperforming the standard of care treatment.

We are thrilled to unveil our all-new website, marking an important milestone for Reglagene!